Neurogene (NGNE) Set to Post Quarterly Earnings on Thursday

Neurogene (NASDAQ:NGNE) will likely be announcing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($1.49) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). On average, analysts expect Neurogene to post ($5.88) EPS for the current fiscal year and ($6.23) EPS for the next fiscal year.

Neurogene Trading Up 3.4%

NGNE stock opened at $27.58 on Thursday. Neurogene has a 1-year low of $15.93 and a 1-year high of $43.66. The business’s 50 day moving average is $29.97 and its 200-day moving average is $27.86.

Analysts Set New Price Targets

Several research firms recently commented on NGNE. JPMorgan Chase & Co. began coverage on Neurogene in a research report on Thursday, October 8th. They set an “overweight” rating and a $60.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and set a $65.00 price objective on shares of Neurogene in a research note on Wednesday, October 28th. Guggenheim increased their price objective on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen cut Neurogene from a “sell” rating to a “strong sell” rating in a report on Saturday, October 10th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Neurogene presently has a consensus rating of “Buy” and a consensus price target of $80.29.

Neurogene Company Profile

Neurogene Inc (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.

Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis.